Gamma-aminobutyric acid type A receptor (benzodiazepine site) (GABAA receptor)

The Gamma-aminobutyric acid type A receptor (GABAA receptor) is a pentameric ligand-gated ion channel that mediates fast inhibitory neurotransmission in the central nervous system. It is composed of five subunits, commonly two α, two β, and one γ or other auxiliary subunits, forming a central chloride ion channel. The benzodiazepine-binding site is located at the interface between the α and γ subunits, classically targeted by drugs such as diazepam, alprazolam, and zolpidem. Allosteric modulators can enhance or inhibit receptor activity, affecting neuronal excitability, and influencing mood, sleep, anxiety, and seizure threshold. The GABAA receptor is a validated target in neuroscience and psychiatry, and its subunit heterogeneity provides subtype-selective pharmacological opportunities. Dysfunction is implicated in anxiety disorders, epilepsy, insomnia, schizophrenia, and other neurological or psychiatric diseases[1][3][4][5][6][7].

Other names

GABAA receptorGABA-benzodiazepine receptorGABAA-BZD receptorbenzodiazepine receptor

Positive allosteric modulation (benzodiazepines: increase frequency of channel opening); Negative allosteric modulation (some ligands antagonize or inhibit channel activity); Direct agonism (GABA, muscimol); Direct antagonism (flumazenil blocks BZD effects)